

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. DO NOT EXCEED FIVE PAGES.

NAME: Stephenson, Ryan

eRA COMMONS USER NAME (credential, e.g., agency login):

POSITION TITLE: Assistant Professor of Obstetrics, Gynecology and Reproductive Sciences

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	END DATE MM/YYYY	FIELD OF STUDY
Boston College, Chestnut Hill, MA	BA	2005	Mathmatics
Rowan University School of Osteopathic Medicine, Stratford, NJ	DO	2014	Medicine
University of Connecticut School of Medicine, Farmington, CT	DO	2015	Internship in Internal Medicine
University of Connecticut School of Medicine, Farmington, CT	DO	2017	Residency in Internal Medicine
Rutgers University, Robert Wood Johnson Medical School, New Brunswick, NJ	DO	2020	Fellowship in Hematology/Oncology
Rutgers University, Robert Wood Johnson Medical School, New Brunswick, NJ	DO	2020	Chief Fellow in Hematology/Oncology

A. Personal Statement

I am a medical oncologist with the Urologic Oncology and Skin and Soft Tissue Oncology Programs at Rutgers Cancer Institute of New Jersey and also affiliated with RWJ University Hospital and RWJ University Hospital Somerset and RWJBarnabas Health Medical Group. I received my undergraduate degree at Boston College where I studied mathematics and chemistry. Following graduation, I worked for several years in clinical research operations at Memorial Sloan-Kettering Cancer Center. It was a formative time for me as I worked on early-phase clinical trials of new therapies for metastatic prostate cancer, many of which later became the standard therapies used to treat patients today. It was my passion for patient care that drove me toward a career as a physician. I attended medical school in New Jersey at Rowan University School of Osteopathic Medicine and completed residency at the University of Connecticut. I then returned to New Jersey and completed a fellowship in hematology and medical oncology at Rutgers Robert Wood Johnson Medical School and Rutgers Cancer Institute of New Jersey, where I also served as Chief Fellow. It is my goal to deliver comprehensive care to each of my patients. I work collaboratively with our multidisciplinary team to provide a personalized approach to each patient's cancer care. Most importantly, I ensure that each of my patient's unique needs and concerns remain paramount. My research interests involve developing novel therapeutics for advanced genitourinary malignancies. As New Jersey's only NCI-Designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey allows me the unique opportunity to collaborate with investigators across disciplines to deliver innovative therapy to each of my patients.

B. Positions, Scientific Appointments and Honors**Positions and Scientific Appointments**

- 2021 - Attending Oncologist, Robert Wood Johnson University Hospital, Robert Wood Johnson Barnabas Health, Somerset, NJ
- 2020 - Assistant Professor of Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ
- 2020 - Academic Oncologist, Robert Wood Johnson University Hospital, Robert Wood Johnson Barnabas Health, New Brunswick, NJ

- 2010 - 2014 Consultant, Prostate Cancer Clinical Trials Consortium, Memorial Sloan-Kettering Cancer Center, New York, NY
- 2009 - 2010 Clinical Research Coordinator, Memorial Sloan-Kettering Cancer Center, New York, NY
- 2007 - 2009 Session Assistant, Memorial Sloan-Kettering Cancer Center, New York, NY
- 2007 - 2009 Research Study Assistant, Memorial Sloan-Kettering Cancer Center, New York, NY

Honors

- 2001 - 2005 Dean's List, Boston College
- 2017 Program Director's Award, Internal Medicine Residency Program, University of Connecticut School of Medicine
- 2012 Alpha Epsilon Lambda Graduate Students Honor Society, University of Medicine & Dentistry of New Jersey
- 2007 Above & Beyond the Call of Duty Award, Memorial Sloan-Kettering Cancer Center
- 2005 Golden Key International Honor Society, Boston College
- 2002 National Society of Collegiate Scholars, Boston College

C. Contribution to Science

1. I am a member of the Clinical Investigations and Precision Therapeutics (CIPT) Program at the Rutgers Cancer Institute of New Jersey. The Overall Goals of the Clinical Investigations and Precision Therapeutics (CIPT) Program are to 1) translate outstanding science across the Cancer Center into early phase trials, 2) develop novel diagnostic, prevention, and therapeutic strategies; and 3) promote bidirectional translation from bench to bedside and back. These goals are supported by close collaborations with the Cancer Metabolism and Immunology (CMI), Genome Instability and Cancer Genetics (GICG), and Cancer Pharmacology (CP) Programs. Translation of population science is done in collaboration with the Cancer Prevention and Control (CPC) Program.
 - a. Cahill EM, Pfail JL, Fu MZ, Saraiya B, Mayer T, Stephenson RD, Ennis RD, Hathout L, Deek MP, Ghodoussipour S, Jang TL. Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT?. *Curr Urol Rep.* 2023 Apr 5; PubMed PMID: 37017928.
 - b. Umbehre MH, Wagg A, Habib MH, Antonelli JA, Chughtai B, Jang TL, Kaldany A, Saraiya B, Stephenson RD, Sze C, Wiedemann A, Jones CA, Schlögl M. Top Ten Tips Palliative Care Clinicians Should Know About Urological Care. *J Palliat Med.* 2023 Feb;26(2):264-269. PubMed PMID: 36579919.
 - c. Davis CH, Ho J, Stephenson R, August DA, Gee H, Weiner J, Alexander HR, Pitt HA, Berger AC. Virtual Tumor Board Increases Provider Attendance and Case Presentations. *JCO Oncol Pract.* 2022 Oct;18(10):e1603-e1610. PubMed PMID: 35939774.

2. Other referenced Original Articles in Journals:
 - a. Autio KA, Pandit-Taskar N, Carrasquillo JA, Stephenson RD, Slovin SF, Rathkopf DE, Hong C, Heller G, Scher HI, Larson SM, Morris MJ. Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer. *Cancer.* 2013 Sep 1;119(17):3186-94. PubMed Central PMCID: PMC3775970.
 - b. Dennis ER, Jia X, Mezheritskiy IS, Stephenson RD, Schoder H, Fox JJ, Heller G, Scher HI, Larson SM, Morris MJ. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. *J Clin Oncol.* 2012 Feb 10;30(5):519-24. PubMed Central PMCID: PMC3295554.
 - c. Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, Delacruz A, Curley T, Schwartz LH, Scher HI. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. *Eur Urol.* 2009 Aug;56(2):237-44. PubMed Central PMCID: PMC2738932.
 - d. Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, Rathkopf D, Gignac GA, Solit D, Schwartz L, Stephenson RD, Hong C, Delacruz A, Curley T, Heller G, Jia X, O'Donoghue J, Larson S, Scher HI. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant

metastatic prostate cancer. J Clin Oncol. 2009 May 20;27(15):2436-42. PubMed Central PMCID: PMC2684850.

Complete List of Published Work in My Bibliography:

<https://www.ncbi.nlm.nih.gov/myncbi/cheryl.riga.1/bibliography/public/>